MIM
DMAC icon

MetLife Investment Management’s DiaMedica Therapeutics DMAC Stock Holding History

MetLife Investment Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80.3K Sell
11,863
-7,222
-38% -$57.2K ﹤0.01% 2616
2025
Q4 		$152K Buy
19,085
+9,018
+90% +$67.4K ﹤0.01% 2407
2025
Q3 		$69.2K Buy
+10,067
New +$54.6K ﹤0.01% 2763

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MetLife Investment Management's DMAC Position: Q1 2026 in Review

MetLife Investment Management reduced its DiaMedica Therapeutics (DMAC) stake by 38% in Q1 2026, selling an estimated $57.2K and leaving 11,863 shares worth $80.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2616.

MetLife Investment Management first reported a position in DMAC in Q3 2025 and has held it in 3 quarters since. The position peaked at $152K in Q4 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • MetLife Investment Management held 11,863 shares of DiaMedica Therapeutics worth $80.3K as of Q1 2026.
  • MetLife Investment Management sold 7,222 DiaMedica Therapeutics shares in Q1 2026, an estimated $57.2K.
  • DiaMedica Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2616 holding.
  • MetLife Investment Management first reported a position in DiaMedica Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • MetLife Investment Management's DiaMedica Therapeutics position peaked at $152K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.